Use of compounds comprising a nitrogen-oxygen heterocycle

Abstract

Die invention relates to the use of compounds of the general formula (I) wherein Y is a C 1-3 -alkenylene group, wherein B is selected from the group, which consists of C 1-26 -alkenylene groups, wherein one C-atom is replaced by an oxygen atom and one C-atom is replaced by a sulphur atom or two C-atoms may be replaced by a S-heterocycle, and wherein X represents the organo phosphorous group or the amino group for inhibition of the 1-deoxy-D-xylulose-5-phosphate-(DOXP)-metabolic pathway, use thereof as a herbicide and for the preparation of a pharmaceutical preparation as well as a method for the therapeutic and prophylactic treatment of infections in humans and animals, caused by viruses, bacteria, fungi and parasites.

1 . Use of compounds of the general formula (I)  
       
         
           
           
               
               
           
         
         wherein Y is a C 1-3 -alkenylene group, which is substituted by the substituents R 1  and R 2  and optionally by the substituents R 3  to R6,  
         wherein R 1  to R8 are the same or different and are selected from the group, which consists of hydrogen, hydroxy, halogen, substituted and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl-(C 0-26 )-alkyl groups, substituted and unsubstituted cycloalkoxy-(C 0-26 )-alkyl groups, substituted and unsubstituted alkoxy (C 0-26 )-alkyl groups, substituted and unsubstituted amino groups and substituted, unsubstituted thio-(C 0-26 )-alkyl groups, substituted and insubstituted Sulfonyl-(C 0-26 )-alkyl groups, substituted and unsubstituted suinMyl-(C 0-26 )-alkyl groups and substituted or unsubstituted acyl radicals, wherein each alkyl radical, each alkoxy radical and each acyl radical branched or unbranched and each alkyl radical, each alkoxy radical and each cycloalkyl group may be saturated or unsaturated having one or more double or triple bonds and one or two carbon atoms of the cycloalkyl groups may be replaced by nitrogen, oxygen or sulphur atoms and  
         R 13  and R 14  are defmed like R 1  to R 8  or together form an oxo group,  
         wherein X represents the organo phosphorous group  
         
           
             
             
                 
                 
             
           
         
         wherein R 9  and R 10  are the same or different and are selected from the group, which consists of hydrogen, substituted and unsubstituted (C 1-26 )-alkyl groups, substituted and unsubstituted Hydroxy-(C 1-26 )-alkyl groups, substituted and unsubstituted cycloalkyl-(C 0-26 )-alkyl groups, substituted and unsubstituted acyl, halogen, OX 9  or OX 10 , wherein each alkyl radical, each alkoxy radical and each acyl radical branched or unbranched and each alkyl radical, each alkoxy radical and each cycloalkyl group may be saturated or unsaturated having one or more double or triple bonds and one or two carbon atoms of the cycloalkyl groups may be replaced by nitrogen, oxygen or sulphur atoms,  
         wherein X 9  or X 10  may be identical or different and are selected from the group, which consists of hydrogen, substituted and unsubstituted (C 1-26 )-alkyl groups, substituted and unsubstituted hydroxy-(C 1-26 )-alkyl groups, substituted and unsubstituted cycloalkyl-(C 0-26 )-alkyl groups, substituted and unsubstituted acyl silyl, a cation of an organic and inorganic base, in particular of a metal of main group I, II or III of the periodic system, ammonium, substituted ammonium and amnmonium compounds which are derived from ethylenediamine or amino acids, wherein each alkyl radical, each alkoxy radical and each acyl radical branched or unbranched and each alkyl radical, each alkoxy radical and each cycloalkyl group saturated or may be unsaturated having one or more double or triple bonds and one or two carbon atoms of the cycloalkyl groups may be replaced by nitrogen, oxygen or sulphur atoms,  
         or wherein X represents the amino group  
         
           
             
             
                 
                 
             
           
         
         wherein R 11  and R 12  are the same or different and are selected from the group, which consists of hydrogen, substituted and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl-(C 0-26 )-alkyl groups, substituted and unsubstituted cycloalkoxy-(C 0-26 )-alkyl groups, substituted and unsubstituted alkoxy (C 0-26 )-alkyl groups and substituted or unsubstituted acyl radicals, wherein each alkyl radical, each alkoxy radical and each acyl radical branched or unbranched and each alkyl radical, each alkoxy radical and each cycloalkyl group may be saturated or unsaturated with one or more double or triple bonds and one or two carbon atoms of the cycloalkyl groups may be replaced by nitrogen, oxygen or sulphur atoms,  
         wherein B is selected from the group, which consists of substituted and unsubstituted C 1-26 -alkenylene groups, wherein one C-atom may be replaced by an oxygen atom and one C-atom may be replaced by a sulphur atom or two C-atoms may be replaced by a S-heterocycle and wherein each alkylene radical may be branched or unbranched and may be saturated or unsaturated with one or more double or triple bonds and may be substituted with one or more hydroxy groups, halogen groups or oxo groups, or their pharmaceutically acceptable salts, esters and salts of the esters for the inhibition of the 1-deoxy-D-xylulose-5-phosphate-(DOXP)-metabolic pathway.  
       
     
     
         2 . Use according to  claim 1 , characterised in that and R 13  and R 14  together form an oxo group in α-position to the nitrogen atom.  
     
     
         3 . Use according to  claim 1  or  claim 2 , characterised in that Y represents a methylene group, which preferably is substituted with two methyl groups.  
     
     
         4 . Use according to one of the preceding claims, characterised in that B represents ether group (II)  
       —A 1 —O—A 2 —  (II) wherein A 1  is absent or is a (C 1-9 )-alkylene radical, and    A 2  is absent or is selected from the group, which consists of (C 1-9 )-alkylene radicals, a sulphur atom and a (C 3-8 )-heterocycle, which comprises at least one sulphur atom.    
     
     
         5 . Use according to  claim 4 , characterised in that A 1  and A 2  each represent a methylene group.  
     
     
         6 . Use according to one of  claims 1  to  3 , characterised in that B represents keto group (III)  
       
         
           
           
               
               
           
         
         wherein A 3  and A 4,  out of which one or both may be absent, are the same or different, are selected from the group, which consists of (C 1-9 )-alkylene radicals,  
         wherein all the (C 1-9 )-alkylene radicals may be branched or unbranched, may comprise one or more double bonds or may be substituted with a hydroxyl group or a halogen group.  
       
     
     
         7 . Use according to  claim 6 , characterised in that 
 A 3  is absent and A 4  represents a methylene or an ethylene group.    
     
     
         8 . Use according to one of  claims 1  to  2 , characterised in that B represents a 2-hydroxypropylene group.  
     
     
         9 . Use according to  claim 1 , characterised in that the compound is selected from the group, which consists of  
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         10 . Use according to  claim 9 , characterised in that the compound is selected from the group, which consists of  
       
         
           
           
               
               
           
         
       
     
     
         11 . Use of an active substance defined according to one of  claims 1  to  10  for the preparation of a pharmaceutical preparation for the treatment of infectious processes in humans and animals, caused by viruses, bacteria, fungi or parasites.  
     
     
         12 . Use of an active ingredient defined according to one of  claims 1  to  10  as a herbicide.  
     
     
         13 . Use according to  claim 11  for the preparation of a pharmaceutical preparation for the treatment of infections, caused by bacteria, which are selected from the group, which consists of bacteria of the family Propionibacteriaceae, in particular the genus Propiomibacterium, in particular species  Propionibacterium acnes , bacteria of the family Actinomycetaceae, in particular the genus Actinomyces, bacteria of the genus Corynebacterium, in particular the species  Corynebacterium diphteriae  and  Corynebacterium pseudotuberculosis , bacteria of the family Mycobacteriaceae, the genus Mycobacterium, in particular the species  Mycobacterium leprae, Mycobacterium tuberculosis, Mycobacterium bovis  and  Mycobacterium avium , bacteria of the family Chlamydiaceae, in particular the species  Chlamydia trachomatis  and  Chlamydia psittaci , bacteria of the genus Listeria, in particular the species  Listeria monocytogenes , bacteria of the species  Erysipelthrix rhusiopathiae , bacteria of the genus Clostridium, bacteria of the genus Yersinia, of the species  Yersinia pestis, Yersinia pseudotuberculosis, Yersinia enterocolitica  and  Yersinia ruckeri , bacteria of the family Mycoplasmataceae, of the genera Mycoplasma and Ureaplasma, in particular the species  Mycoplasma pneumoniae , bacteria of the genus Brucella, bacteria of the genus Bordetella, bacteria of the family Neisseriaceae, in particular of the genera Neisseria and Moraxella, in particular the species  Neisseria meningitides, Neisseria gonorrlhoeae  and  Moraxella bovis , bacteria of the family Vibrionaceae, in particular of the genera Vibrio, Aeromonas, Plesiomonas and Photobacterium, in particular the species  Vibrio cholerae, Vibrio anguillarum  and  Aeromonas salmonicidas , bacteria of the genus Camnpylobacter, in particular the species  Campylobacter jejuni, Campylobacter coli  and  Carnpylobacter fetus , bacteria of the genus Helicobacter, in particular the species  Helicobacter pylori , bacteria of the families Spirochaetaceae and Leptospiraceae, in particular the genera Treponema, Borrelia and Leptospira, in particular  Borrelia burgdorferi , bacteria of the genus Actinobacillus, bacteria of the family Legionellaceae, the genus Legionella, bacteria of the family Rickettsiaceae and family Bartonellaceae, bacteria of the genera Nocardia and Rhodococcus, bacteria of the genus Dermatophilus, bacteria of the family Pseudomonadaceae, in particular the genera Pseudomonas and Xanthomonas, bacteria of the family Enterobacteriaceae, in particular the genera Escherichia, Klebsiella, Proteus, Providencia, Salmonella, Serratia and Shigella, bacteria of the family Pasteurellaceae, in particular the genus Haemophilus, bacteria of the family Micrococcaceae, in particular the genera Micrococcus and Staphylococcus, bacteria of the family Streptococcaceae, in particular the genera Streptococcus and Enterococcus and bacteria of the family Bacillaceae, in particular the genera Bacillus and Clostridium, and in the eradication of Helicobacter in ulcers of the gastrointestinal tract.  
     
     
         14 . Use according to  claim 1  I for the preparation of a pharmaceutical preparation for the treatment of infections caused by viruses, which are selected from the group, which consists of viruses of the genus Parvoviridae, in particular parvoviruses, dependoviruses, densoviruses, Adenoviridae, in particular adenoviruses, mastadenoviruses, aviadenoviruses viruses of the genus Papovaviridae, in particular papovaviruscs, in particular papillomaviruses (‘wart” viruses), polyomaviruses, in particular JC virus, BK virus and miopapovaviruses, viruses of the genus Herpesviridae, in particular herpes simplex viruses, varicella-zoster viruses, human cytomegalovirus, Epstein-Barr viruses, human herpesvirus 6, human herpesvirus 7, human herpesvirus 8, viruses of the genus Poxiviridae, in particular poxviruses, orthopoxviruses, parapoxviruses, molluscum contagiosum virus, aviviruses, capriviruses, leporipoxviruses, primarily hepatotropic viruses, in particular hepatitisviruses, such as hepatitis A viruses, hepatitis B viruses, hepatitis C viruses, hepatitis D viruses, hepatitis E viruses, hepatitis F viruses, hepatitis G viruses, hepadnaviruses, in particular all hepatitisviruses, such as hepatitis B virus, hepatitis D viruses, viruses of the genus Picornaviridae, in particular picomaviruses, all enteroviruses, all polioviruses, all coxsackieviruses, all echoviruses, all rhinoviruses, hepatitis A virus, aphthoviruses, viruses of the genus Calciviridae, in particular hepatitis E viruses, viruses of the genus Reoviridae, orbiviruses, rotaviruses, viruses of the genus Togaviridae, in particular togaviruses, alphaviruses, rubiviruses, pestiviruses, rubellavirus, viruses of the genus Flaviviridae, in particular flaviviruses, FSME virus, hepatitis C virus, viruses of the genus Orthomyxoviridae, in particular influenza viruses, viruses of the genus Paramyxoviridae, in particular pararnyxoviruses, morbillivirus, pneumovirus, measles virus, mumps virus, viruses of the genus Rhabdoviridae, in particular rhabdoviruses, rabies virus, lyssavirus, vascular stomatitisvirus, viruses of the genus Coronaviridae, in particular coronaviruscs, viruses of the genus Bunyaviridae, in particular bunyaviruscs, nairovirus, phlebovirus, uukuvirus, hantavirus, hantaan virus, viruses of the genus Arenaviridae, in particular arenaviruscs, lymphocytic choriomeningitis virus, viruses of the genus Retroviridae, in particular retroviruses, all HTL viruses, human T-cell leukaemia virus, oncomaviruses, spumaviruses, lentiviruses, all HI viruses, viruses of the genus Filoviridae, in particular Marburg and Ebola virus, slow viruses, prions, oncoviruses and leukaemia viruses.  
     
     
         15 . Use according to  claim 11  for the preparation of a pharmaceutical preparation for the prophylaxis and treatment of infections caused by unicellular parasites, namely the causative organisms of malaria and sleeping sickness and of Chagas' disease, toxoplasmosis, amoebic dysentery, leishmaniases, trichomoniasis, pneurnocystosis, balantidiasis, cryptosporidiosis, sarcocytosis, acanthamoebosis, naeglerosis, coecidiosis, giardiasis and lambliasis.  
     
     
         16 . Method for the treatment of infectious diseases, caused by bacteria, fungi or parasites, in which a therapeutically active amount of a compound defined according to  claims 1  to  10  compound is administered to a patient who is taken ill with an infection caused by bacteria, fungi or parasites.